However, the uncertainty with respect to the number of MYCN gene copies, eventually classified as MYCN gain, and the natural history of other NB patients with constitutional 2p duplication were the two rationales for choosing an intensified strategy of treatment to address the anticipated aggressive biology of the tumor. The gene discussed is MYCN; the disease is neuroblastoma.